Mesoblast Ltd
MESO15.950USD
-0.130-0.81%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
2.04BValor de mercado
PerdaP/L TTM
Mais detalhes de Mesoblast Ltd Empresa
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Informações de Mesoblast Ltd
Código da empresaMESO
Nome da EmpresaMesoblast Ltd
Data de listagemDec 16, 2004
CEOItescu (Silviu)
Número de funcionários81
Tipo de títulosDepository Receipt
Fim do ano fiscalDec 16
EndereçoL 38 55 Collins St
CidadeMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3000
Telefone61396396036
Sitehttps://www.mesoblast.com/
Código da empresaMESO
Data de listagemDec 16, 2004
CEOItescu (Silviu)
Executivos da empresa Mesoblast Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+30310.00%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Horst, Ph.D.
Mr. Justin Horst, Ph.D.
Head - Manufacturing
Head - Manufacturing
--
--
Mr. Michael Schuster
Mr. Michael Schuster
Pharma Partnering
Pharma Partnering
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+30310.00%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 5 de fev
Atualizado em: qui, 5 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Gueck (William J)
4.97%
Legal & General Investment Management Ltd.
0.50%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Outro
93.59%
Investidores
Investidores
Proporção
Gueck (William J)
4.97%
Legal & General Investment Management Ltd.
0.50%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Outro
93.59%
Tipos de investidores
Investidores
Proporção
Individual Investor
5.06%
Investment Advisor
1.45%
Research Firm
0.83%
Investment Advisor/Hedge Fund
0.68%
Hedge Fund
0.02%
Venture Capital
0.01%
Outro
91.94%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
140
3.87M
3.00%
-443.29K
2025Q3
134
3.48M
2.71%
-1.10M
2025Q2
126
4.04M
3.16%
+542.30K
2025Q1
132
4.07M
3.19%
+9.28K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Gueck (William J)
6.42M
5%
+6.42M
--
Sep 12, 2025
Legal & General Investment Management Ltd.
651.42K
0.51%
+651.42K
--
Sep 30, 2025
Morgan Stanley & Co. International Plc
413.52K
0.32%
+100.00K
+31.90%
Sep 30, 2025
Goldman Sachs & Company, Inc.
407.28K
0.32%
-8.19K
-1.97%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
376.17K
0.29%
-122.83K
-24.61%
Sep 30, 2025
Susquehanna International Group, LLP
271.49K
0.21%
+36.90K
+15.73%
Sep 30, 2025
Arax Advisory Partners
200.08K
0.16%
+200.08K
--
Sep 30, 2025
Summit Wealth Strategies
199.29K
0.16%
+1.13K
+0.57%
Jun 30, 2025
Aperio Group, LLC
137.23K
0.11%
+2.06K
+1.52%
Sep 30, 2025
BofA Global Research (US)
111.46K
0.09%
+98.96K
+791.74%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
iShares Biotechnology ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
Proporção0.1%
Invesco Nasdaq Biotechnology ETF
Proporção0.08%
ProShares Ultra Nasdaq Biotechnology
Proporção0.08%
ActivePassive International Equity ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Data
Data ex-dividendo
Tipo
Proporção
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
